Sana Biotechnology
Engineers immune-evading cells and in vivo CAR T therapies for diabetes and B-cell disease.
$3.95
After-hours close+0.02 (+0.51%)
At close$3.93(−3.91%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.18 | — | — |
| Aug 2026 | −$0.15 | −$0.22 | −49.8% |
| Aug 2026 | −$0.15 | −$0.13 | +11.5% |
| May 2026 | −$0.15 | −$0.14 | +6.7% |
| Mar 2026 | −$0.13 | −$0.16 | −23.1% |
The latest year is open to everyone — the 24 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Feb 2021 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.18 | — | — | — | — | — |
| Aug 11, 2026 | −$0.15 | −$0.22 | −49.8% | — | — | — |
| Aug 10, 2026 | −$0.15 | −$0.13 | +11.5% | — | — | — |
| May 11, 2026 | −$0.15 | −$0.14 | +6.7% | — | — | — |
| Mar 3, 2026 | −$0.13 | −$0.16 | −23.1% | — | — | — |
The latest year is open to everyone — the 24 quarters behind it read with an account. Sign in | ||||||
| Nov 6, 2025 | ||||||
| Aug 11, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 17, 2025 | ||||||
| Nov 8, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 29, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 8, 2023 | ||||||
| Mar 16, 2023 | ||||||
| Nov 2, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 10, 2022 | ||||||
| Mar 16, 2022 | ||||||
| Nov 8, 2021 | ||||||
| Aug 4, 2021 | ||||||
| May 5, 2021 | ||||||
| Mar 24, 2021 | ||||||
| Feb 5, 2021 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||